Pharmacokinetics of new antiepileptic drugs and individualized therapy in pregnant women
| Project/Area Number |
16K18931
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Okayama University (2017)
Chiba University (2016) |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2017: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
|---|
| Keywords | 個別適正化 / 薬物動態 / てんかん / 抗てんかん薬 / ラモトリギン / 個別化医療 / レベチラセタム / TDM / オーダーメイド医療 |
|---|
| Outline of Final Research Achievements |
Lamotrigine (LTG) is widely used among newer antiepileptic drugs in pregnant women with epilepsy. LTG is metabolized via glucuronidation by UGT1A4, and the main metabolite, LTG-2N-glucuronide is excreted in urine. The present study demonstrated that LTG clearance was well correlated with plasma LTG-2N-glucuronide/LTG ratio. Since UGT1A4 expression was induced during pregnancy, plasma LTG-2N-glucuronide/LTG ratio might be useful in individualized therapy with LTG in pregnant women.
|
Report
(3 results)
Research Products
(5 results)
